These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28891401)

  • 21. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
    Rosenfield K; Jaff MR; White CJ; Rocha-Singh K; Mena-Hurtado C; Metzger DC; Brodmann M; Pilger E; Zeller T; Krishnan P; Gammon R; Müller-Hülsbeck S; Nehler MR; Benenati JF; Scheinert D;
    N Engl J Med; 2015 Jul; 373(2):145-53. PubMed ID: 26106946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrograde Popliteal Access to Percutaneous Peripheral Intervention for Chronic Total Occlusion of Superficial Femoral Arteries.
    Dumantepe M
    Vasc Endovascular Surg; 2017 Jul; 51(5):240-246. PubMed ID: 28595481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization.
    Krankenberg H; Tübler T; Sixt S; Fischer M; Schmiedel R; Schulte KL; Balzer JO; Kieback A; Fiehn E; Wittenberg G; Ali T; Tiefenbacher C; Jahnke T; Steinkamp HJ; Wegscheider K; Treszl A; Ingwersen M; Zeller T
    J Endovasc Ther; 2014 Aug; 21(4):463-71. PubMed ID: 25101571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial.
    Bosiers M; Deloose K; Callaert J; Verbist J; Hendriks J; Lauwers P; Schroë H; Lansink W; Scheinert D; Schmidt A; Zeller T; Beschorner U; Noory E; Torsello G; Austermann M; Peeters P
    J Endovasc Ther; 2015 Feb; 22(1):1-10. PubMed ID: 25775672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease.
    Stavroulakis K; Schwindt A; Torsello G; Beropoulis E; Stachmann A; Hericks C; Bollenberg L; Bisdas T
    J Endovasc Ther; 2018 Feb; 25(1):92-99. PubMed ID: 29251204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results.
    Lammer J; Bosiers M; Deloose K; Schmidt A; Zeller T; Wolf F; Lansink W; Sauguet A; Vermassen F; Lauwers G; Scheinert D; Popma JJ; McGreevy R; Rapoza R; Schwartz LB; Jaff MR
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1178-87. PubMed ID: 27282601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-Helix Stenting in 1 Superficial Femoral Artery.
    Jong BH; Soga Y
    JACC Cardiovasc Interv; 2018 Aug; 11(15):e121-e122. PubMed ID: 29778729
    [No Abstract]   [Full Text] [Related]  

  • 28. Superficial Femoral Artery in-Stent Restenosis Treated with Paclitaxel-Coated Balloon Angioplasty - Results of Three-Year Follow-Up.
    Peclat de Oliveira JC; Alvim Fiorelli RK; Rolim Maia Peclat AP; Peclat de Oliveira LM; Oliveira R; Belczac SQ; Almeida RS; Dalio MB; Joviliano EE; Gutfilen B
    Vasc Endovascular Surg; 2023 Oct; 57(7):673-679. PubMed ID: 36945834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis.
    Ho KJ; Devlin PM; Madenci AL; Semel ME; Gravereaux EC; Nguyen LL; Belkin M; Menard MT
    J Vasc Surg; 2017 Mar; 65(3):734-743. PubMed ID: 27986482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial).
    Bague N; Julia P; Sauguet A; Pernès JM; Chatelard P; Garbé JF; Penillon S; Cardon JM; Commeau P; Planché O; Guyomarch B; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2017 Jan; 53(1):106-113. PubMed ID: 27890526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
    Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
    J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter.
    Tepe G; Gögebakan Ö; Redlich U; Tautenhahn J; Ricke J; Halloul Z; Meyer DR; Waliszewski M; Schnorr B; Zeller T; Müller-Hülsbeck S; Ott I; Albrecht T
    Cardiovasc Intervent Radiol; 2017 Oct; 40(10):1535-1544. PubMed ID: 28660441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smaller Superficial Femoral Artery is Associated with Worse Outcomes after Percutaneous Transluminal Angioplasty for De Novo Atherosclerotic Disease.
    Chang H; Veith FJ; Rockman CB; Cayne NS; Babaev A; Jacobowitz GR; Ramkhelawon B; Patel VI; Garg K
    Ann Vasc Surg; 2021 Oct; 76():38-48. PubMed ID: 33838233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
    Herten M; Torsello GB; Schönefeld E; Imm B; Osada N; Stahlhoff S
    J Vasc Surg; 2015 Feb; 61(2):394-9. PubMed ID: 25307133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.
    Virga V; Stabile E; Biamino G; Salemme L; Cioppa A; Giugliano G; Tesorio T; Cota L; Popusoi G; Pucciarelli A; Esposito G; Trimarco B; Rubino P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):411-5. PubMed ID: 24630884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.